Maria A. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Evaluation of Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 and Pembrolizumab in HPV16-positive Head and Neck Squamous Cell Carcinoma
- Evaluation of Ficerafusp Alfa and Pembrolizumab Combination in PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 26 of 140 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating head and neck squamous cell carcinoma, with particular emphasis on advanced disease states including recurrent and metastatic conditions.
- Head and neck cancer therapeutics
- Advanced oncology treatments
- Metastatic disease management
Through clinical research, the investigator explores novel therapeutic approaches for patients with progressive head and neck cancers.
Immunotherapy Research
The investigator focuses on advancing immunotherapy treatments, particularly examining the role of PD-L1 positive cancer responses in head and neck cancer patients.
- Immune checkpoint inhibition
- Targeted therapy combinations
- PD-L1 expression studies
The research encompasses innovative combination approaches in immunotherapy for enhanced treatment outcomes.
Treatment Innovation
Active in developing combination therapy strategies, the investigator studies novel therapeutic agents in conjunction with established treatments for head and neck cancer.
- Novel therapeutic combinations
- Treatment resistance mechanisms
- Clinical efficacy assessment
The investigator evaluates emerging treatment modalities to improve outcomes in advanced head and neck cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.